Abstracts tagged "Disease Activity"

Abstract Number: 2663 • 2015 ACR/ARHP Annual Meeting
Evaluation of Anti-Cyclic Citrullinated Peptide Autoantibody Levels in Clinical Practice and Its Association with Disease Activity
E Alemao¹, KK Gandhi¹, C Iannaccone², M Frits², JS Coblyn², N Shadick² and Michael Weinblatt², ¹Bristol-Myers Squibb, Princeton, NJ, ²Brigham and Women's Hospital, Boston, MA
Background/Purpose: Testing for anti-citrullinated peptide antibodies (ACPA) is included in the 2010 ACR classification criteria for RA. ACPA concentration, beyond ACPA positivity, is indicative of…
Abstract Number: 3045 • 2015 ACR/ARHP Annual Meeting
Anti-Alpha-Enolase Antibodies in Behçet’s Disease: A Marker of Articular Disease Activity?
Leandro L. Prado, Celio R. Gonçalves, Vilma S. T. Viana, Eloisa Bonfá and Carla G.S. Saad, Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: Diagnosis of Behçet´s disease (BD) is challenging because is based solely on clinical features. Articular involvement in this disease may mimic other diagnosis such…
Abstract Number: 169 • 2015 ACR/ARHP Annual Meeting
Ultrasonographic Signs of Inflammation of Metatarsophalangeal Joints in Rheumatoid Arthritis Patients Who Are Treated to Target
Myrthe van der Ven¹, David F. Ten Cate², Andreas Gerards³, Johannes Jacobs⁴, Nanno Swen⁵, M.H. de Jager⁶, Natalja Basoski⁷, Cees Haagsma⁸, Mieke Hazes¹ and J.J. Luime¹, ¹Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ²Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁴Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands, ⁵Rheumatology, Medical Center Alkmaar, Alkmaar, Netherlands, ⁶Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, Netherlands, ⁷Rheumatology, Maasstadziekenhuis, Rotterdam, Netherlands, ⁸Rheumatology, Ziekenhuisgroep Twente, Almelo, Netherlands
Background/Purpose: The feet are often involved in rheumatoid arthritis (RA), but physical examination of the metatarsophalangeal (MTP) joints to detect arthritis is challenging especially in…
Abstract Number: 533 • 2015 ACR/ARHP Annual Meeting
The Interferon Gene Signature in Early Rheumatoid Arthritis Demonstrates No Significant Association with Disease Activity
Faye A H Cooles¹, Amy E. Anderson², Catharien Hilkens³ and John D Isaacs⁴, ¹Musculoskeletal Research Group, Newcastle University, Newcastle upon Tyne, United Kingdom, ²Musculoskeletal Research Group, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom, ³Musculoskeletal Research Group, Newcastle University, Newcastle Upon Tyne, United Kingdom, ⁴Newcastle University and the Freeman Hospital, Newcastle-upon-Tyne, United Kingdom
Background/Purpose: An interferon-α gene signature (IGS) has been demonstrated in a number of rheumatological conditions, including rheumatoid arthritis (RA) where it is present in about…
Abstract Number: 735 • 2015 ACR/ARHP Annual Meeting
Belimumab Reduces the Frequency of Flares and Prevents Damage Progression in SLE Patients: Experience in a Clinical Practice Setting
Luca Iaccarino¹, Silvano Bettio¹, Rossella Reggia², Margherita Zen³, Micol Frassi², Laura Andreoli², Linda Nalotto¹, Mariele Gatto¹, Lara Pea², Nicola Bassi¹, Maddalena Larosa¹, Alessandra Zanola², Leonardo Punzi⁴, Angela Tincani² and Andrea Doria¹, ¹Department of Medicine-DIMED, University of Padova, Padova, Italy, ²Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ³Division of Rheumatology, University of Padova, Padova, Italy, ⁴Unit of Rheumatology, University of Padova, Padova, Italy
Background/Purpose: To investigate the efficacy and safety of belimumab in patients affected with active systemic lupus erythematosus (SLE) refractory to standard therapy. Methods: Fifty-eight patients,…
Abstract Number: 1550 • 2015 ACR/ARHP Annual Meeting
Flares of Disease Activity As Risk Factor for the Occurrence of Myocardial Infarction in Patients with Rheumatoid Arthritis
Esmee Bakker¹, Pauline Geuijen², Beata Radovits¹, Delia Popa-Diaconu¹, Calin Popa¹, Elke Arts¹, Alfons A. den Broeder³ and Jaap Fransen¹, ¹Rheumatology, Radboud University Medical Centre, Nijmegen, Netherlands, ²Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular diseases (CVD). The underlying mechanism is partly explained by the inflammation process in both…
Abstract Number: 2069 • 2015 ACR/ARHP Annual Meeting
High Interferon Gene Signature Is Associated with Increased Disease Activity, Reduced Complement C3 and C4, and Increased Oral Corticosteroid Use in Systemic Lupus Erythematosus (SLE)
K Ranade, L Wang, P Brohawn, W Greth, J Drappa and G Illei, MedImmune, Gaithersburg, MD
Background/Purpose: Increased expression of genes inducible by type 1 interferons has been observed in a subset of patients with systemic lupus erythematosus (SLE). Oral corticosteroids…
Abstract Number: 2532 • 2015 ACR/ARHP Annual Meeting
Disease Activity in Women with Systemic Lupus Erythematosus during Pregnancy and the First Year Post Partum
Carina Gotestam Skorpen^1,2, Johan Skomsvoll³, Inge-Margrethe Gilboe⁴, Stian Lydersen⁵ and Marianne Wallenius³, ¹Dept of Neuroscience, Norwegian University of Science and Technology (NTNU), Trondheim, Norway, ²Dept of Rheumatology, Trondheim University Hospital, Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases, Trondheim, Norway, ³Dept of Rheumatology, Trondheim University Hospital, National Advisory Unit on Pregnancy and Rheumatic Diseases, Trondheim, Norway, ⁴Revmatologisk avdeling seksjon, Oslo universitetssykehus HF, Rikshospitalet, Oslo, Norway, ⁵Regional Center for the health of children and adolescents, Norwegian University of Science and Technology (NTNU), Trondheim, Norway
Disease Activity in women with SLE during pregnancy and the first year post partumBackground/Purpose: Disease activity measured by validated methods has been sparsely examined during…
Abstract Number: 2672 • 2015 ACR/ARHP Annual Meeting
Determinants of Patient- Physician Discordance in Assessment of Global Disease Activity in Latinos with Rheumatoid Arthritis in the United States
George A. Karpouzas¹, Taylor Draper², Elizabeth Hernandez¹ and Sarah Ormseth¹, ¹Rheumatology, Harbor-UCLA Medical Center, Torrance, CA, ²Psychology, Loma Linda University, Loma Linda, CA
Background/Purpose: Patients and physicians often differ in their perceptions of disease activity in Rheumatoid arthritis (RA) as described by patients' and evaluators' global assessments (PGA…
Abstract Number: 3058 • 2015 ACR/ARHP Annual Meeting
NMR-Based Metabolomics Provides New Insights into the Inflammatory Processes in Takayasu Arteritis
Ramnath Misra¹, Anupam Guleria², Durga Prasanna Misra¹, Avadesh Pratap³, Durgesh Dubey⁴, Atul Rawat⁴, Smriti Chaurasia³, C L Khetrapal⁴, Dinesh Kumar⁴ and Paul Bacon⁵, ¹Clinical Immunology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, ²Centre of Biomedical Research, Lucknow, India, ³S.G.P.G.I.M.S, Department of Clinical Immunology, Lucknow, India, ⁴Centre for Biomedical Research, Lucknow, India, ⁵Rheumatology, Birmingham Universit, Birmingham, United Kingdom
Background/Purpose: Takayasu Arteritis (TA), a large vessel disease of unknown aetiology, is the orphan of the inflammatory vasculitides with no evidence base for therapy. It…
Abstract Number: 2913 • 2014 ACR/ARHP Annual Meeting
Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort
Ruediger Mueller¹, Nazim Reshiti², Toni Kaegi³, Axel Finckh⁴, Hendrik Schulze-Koops⁵, Michael H. Schiff⁶ and Johannes von Kempis⁷, ¹Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ²Division of Rheumatology, St. Gallen, Switzerland, ³Division of Rheumatology, Kantonsspital St. Gallen, St. Gallen, Switzerland, ⁴Rheumatology, Geneva University Hospital, Geneva, Switzerland, ⁵Division of Rheumatology and Clinical Immunology, University of Munich, Munich, Germany, ⁶School of Medicine, University of Colorado, Denver, CO, ⁷Rheumatology, St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland
Background/Purpose Anti-inflammatory and disease-modifying properties of glucocorticoids (GCs) have been demonstrated in patients with rheumatoid arthritis (RA). Better outcomes in trials by combinations of synthetic…
Abstract Number: 2518 • 2014 ACR/ARHP Annual Meeting
What Is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors?
Edward C. Keystone¹, Philip Baer², J. Antonio Avina-Zubieta³, Anna Jaroszynska⁴, Jude Rodrigues⁵, Regan Arendse⁶, Dalton Sholter⁷, Michael Starr⁸, Ariel Masetto⁹, John S. Sampalis¹⁰, Emmanouil Rampakakis¹⁰, Francois Nantel¹¹, May Shawi¹¹, Allen J Lehman¹² and Susan Otawa¹², ¹Medicine, University of Toronto, Toronto, ON, Canada, ²Private Practice, Scarborough, ON, Canada, ³Rheumatology, Arthritis Research Centre of Canada, Richmond, BC, Canada, ⁴Private Practice, Burlington, ON, Canada, ⁵Clinical Research and Arthritis Centre, Windsor, ON, Canada, ⁶University of Saskatchewan, Saskatoon, SK, Canada, ⁷University of Alberta, Edmonton, AB, Canada, ⁸Rheumatology, McGill University Health Centre, Montreal, QC, Canada, ⁹Rheumatology, CHUS, Fleurimont, QC, Canada, ¹⁰JSS Medical Research, Montreal, QC, Canada, ¹¹Janssen Inc., Toronto, ON, Canada, ¹²Medical Affairs, Janssen Inc., Toronto, ON, Canada
Background/Purpose: Several standardized response criteria and disease activity indices are used to assess treatment efficacy in rheumatoid arthritis (RA). These measures comprise different types and…
Abstract Number: 2145 • 2014 ACR/ARHP Annual Meeting
Diagnostic Performance and Disease Activity Assessment By FDG-PET in Large-Vessel Vasculitis: A Systematic Literature Review and Meta-Analysis
Michael Soussan¹, Patrick Nicolas², Catherine Schramm³, Sandrine Katsahian³, Veronique Eder⁴, Olivier Fain⁵ and Arsene Mekinian⁶, ¹Nuclear Medicine, Avicennes Hospital, Bobigny, France, ²Pharmacology, Avicenne Hospital, 93000, France, ³Inserm U1138, Centre de Recherche des Cordeliers, Equipe 22, Paris 5, Paris 6, Paris, France, paris, France, ⁴Nuclear Medicine, Avicenne Hospital, Bobigny, France, ⁵Hôpital Saint Antoine, DHU i2B, Service de Médecine Interne, paris, France, ⁶Internal Medicine, DHUi2B Saint Antoine Hospital, paris, France
Background/Purpose: FDG-PET is increasingly used in the work up of large-vessel vasculitis (LVV). The purpose of this study is to perform a systematic review and…
Abstract Number: 1584 • 2014 ACR/ARHP Annual Meeting
Evaluation of the Patient Acceptable Symptom State in Patients with Psoriatic Arthritis
Pinar Cetin¹, Dilek Solmaz², Murat Keser³, Ismail Sari¹, Merih Birlik¹, Nurullah Akkoc¹ and Fatos Onen¹, ¹Rheumatology, Dokuz Eylul University School of Medicine, Izmir, Turkey, ²Department of Internal Medicine, Division of Rheumatology, Namik Kemal University School of Medicine, Tekirdag, Turkey, ³Internal Medicine, Dokuz Eylul University School of Medicine, Izmir, Turkey
Background/Purpose The Patient Acceptable Symptom State (PASS), a single-question outcome, has been defined as an absolute level of patient well-being, which was used in the…
Abstract Number: 1238 • 2014 ACR/ARHP Annual Meeting
Proportion of Peripheral Plasmacytoid Dendritic Cells and Plasmablasts Reflects Disease Activity in IgG4-related Disease
Mitsuhiro Akiyama¹, Katsuya Suzuki¹, Yoshiaki Kassai², Takahiro Miyazaki², Rimpei Morita³, Akihiko Yoshimura³ and Tsutomu Takeuchi¹, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ²Inflammation Drug Discovery Unit, Takeda Pharmaceutical Company Limited, Kanagawa, Japan, ³Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan
Background/Purpose Immunoglobulin (Ig) G4-related disease (IgG4-RD) is a recently recognized fibro-inflammatory disease with multi-organ system involvement. Affected patients frequently have a history of bronchial asthma and allergic rhinitis. The reported pathogenesis of IgG4-RD describes the clear involvement of excessive Th2 cells and regulatory immune reaction in addition to plasma cells 1). However, peripheral immune cell phenotype, which reflects disease status, has not been comprehensively evaluated. Our aim was to definitively determine peripheral blood cell abnormalities and their correlation with disease activity in patients with IgG4-RD.Methods Peripheral blood samples were obtained from active untreated IgG4-RD patients (n=11) and healthy controls (n=16). Comprehensive immunophenotyping assay with information on activation status was done by multi-color flow cytometry, and the proportion of peripheral blood mononuclear cells (PBMCs), including T cells (naïve/memory, Th1/2/17, Treg, and Tfh), B cells (naïve/memory, plasmablast, Breg), monocytes (classical, intermediate, non-classical) and dendritic cells (myeloid, plasmacytoid), and their activity status were precisely defined. Disease activity was measured using the IgG4-RD responder index (RI). Statistical analysis was done using the Mann-Whitney U test and Spearman rank correlation coefficient test.Results The proportion of plasmablasts (CD19+CD20-CD27+CD38+), memory Th2 cells (CD3+CD4+CXCR3-CCR6-CD45RA-), Tregs (CD3+CD4+CD25+CD127low), Tfh (CD3+CD4+CXCR5+), and mDCs (CD3-CD19-CD14-HLA-DR+CD1c+CD303-) in peripheral blood was significantly increased in IgG4-RD patients compared with HC, whereas the proportion of pDCs (CD3-CD19-CD14-HLA-DR+CD1c-CD303+）was significantly decreased. Interestingly, the proportion of pDCs in total DCs was negatively correlated with IgG4-RD RI (r=-0.778, p=0.005) while the proportion of plasmablasts in CD19+cells was positively correlated with RI (r=0.701, p=0.016). Further, the increased proportion of plasmablasts was positively correlated with serum IgG4 level (r=0.718, p=0.013) while the decreased proportion of pDCs tended to be negatively correlated with the number of affected organs (r=-0.518, p=0.061). Conclusion Our comprehensive analysis identified distinct proportional changes in PBMCs in IgG4-RD. In particular, the decrease in pDCs and increase in plasmablasts were strongly linked with disease activity. These combined measurements are expected to be clinically useful surrogate cell markers. This newly identified decrease in circulating pDCs may be involved in the pathogenesis in IgG4-RD via the recently described role in the enhancement of Th2 response 2).References: 1) Stone JH et.al. N Engl J Med 2012;366:539-51 2) Maazi H et.al. Allergy 2013;68:695-701

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].